Savidge Tor C
Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA; Texas Children's Microbiome Center, Texas Children's Children Hospital, Houston, TX, USA.
Curr Opin Pharmacol. 2014 Dec;19:54-60. doi: 10.1016/j.coph.2014.07.009. Epub 2014 Aug 7.
Nitric oxide (NO) produced by the enteric nervous system represents an important regulatory mechanism in gut homeostasis. Aberrant NO signaling contributes significantly toward enteric disease by altering gut motility, vascular tone, blood supply, mucosal barrier function, secretions and immunity. Consequently, there is much interest in therapeutically targeting NO production and its bioactive intermediates. This article highlights recent advances in NO signaling and therapeutics as it relates to the gastrointestinal tract and its associated NO producing microbiota. Because of its limited scope, a particular emphasis is placed on S-nitrosylation as the emerging physiologic mechanism for NO signal transduction, and how such signals are modulated by other gaseous transmitters - notably hydrogen disulfide and carbon monoxide - that are produced by the enteric nervous system and share common molecular targets. Recent findings also indicate that druggable regulators of S-nitrosylation, for example S-nitrosoglutathione (GSNO) reductase, provide for a superior pharmacology and finer therapeutic control over classical NO donors, and may be better suited for oral delivery to the gastrointestinal tract.
由肠道神经系统产生的一氧化氮(NO)是肠道内环境稳定的重要调节机制。异常的NO信号传导通过改变肠道蠕动、血管张力、血液供应、黏膜屏障功能、分泌物及免疫功能,对肠道疾病的发生发展起到了重要作用。因此,针对NO生成及其生物活性中间体的治疗靶点备受关注。本文重点介绍了与胃肠道及其相关产NO微生物群有关的NO信号传导和治疗方面的最新进展。鉴于篇幅有限,本文特别强调了S-亚硝基化作为NO信号转导的新兴生理机制,以及这些信号如何被肠道神经系统产生的、具有共同分子靶点的其他气体递质(尤其是硫化氢和一氧化碳)所调节。最近的研究结果还表明,S-亚硝基化的可药物调节因子,如S-亚硝基谷胱甘肽(GSNO)还原酶,相较于传统的NO供体具有更优的药理学特性和更精细的治疗控制能力,可能更适合口服给药至胃肠道。